Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows ...

As new technology capable of detecting dozens of early-stage cancer types with a single blood test hits the market, support ...

Reading, writing, arithmetic... and cancer. It's not exactly your standard grade school curriculum. This challenging disease ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

Freenome Holdings, Inc., an early cancer detection company developing blood-based screening tests, and Perceptive Capital Solutions Corp , a special purpose acquisition company (SPAC) sponsored by an ...

Leading institutional investors commit $240 million through private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital - - Freenome stockholders ...